London (PRWEB UK) 10 July 2015
Leading Integrated Business Planning solution provider Exceedra has announced that Omega Pharma UK Ltd, a top 5 consumer healthcare company and the fastest growing in UK and Ireland, has selected Exceedra to improve business performance in both volume and commercial finance planning and insight.
The project will focus on improving Trade Promotions Return on Investment as well as providing improved Sales and Operations Planning capability. The project started in May and will go-live later this year.
Omega Pharma UK Ltd is part of the Belgium-based Omega Pharma group, which operates in 35 countries and owns over 2,000 Over the Counter (OTC) brands including Solpadeine, Nytol, TCP, Jungle Formula and Prevalin. It aims to become a global top 10 player in the Over-The-Counter market through the development of innovative prescription-free health and personal care products.
“Like most Consumer Goods Companies, Trade Spend Management is one of the key issues in today’s market, but as anyone who works in our industry will know, looking at this spend in isolation often leads to sub-optimal profit realisation. We needed a solution that not only managed Trade Spend, but also enabled a step change in how we integrate our whole Business Planning process. We selected Exceedra as they have a highly capable and easy-to-use solution that will significantly improve how we plan the business today. Additionally, Exceedra will enable significant financial returns for the UK with the potential to roll out scale benefits into other markets,” said Sue Austin, European S&OP Director for Omega Pharma.
Richard Nicholas, Sales Director of Exceedra, commented, "We're delighted that Omega Pharma has chosen Exceedra to be its Integrated Business Planning partner. We continue to prove to both our customers and the market that we have the leading solutions, market understanding, and delivery capability to solve the key issues faced by consumer goods companies.”